Atlas Capital Advisors Inc. Purchases 8,318 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Atlas Capital Advisors Inc. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5,620.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,466 shares of the biopharmaceutical company's stock after acquiring an additional 8,318 shares during the period. Atlas Capital Advisors Inc.'s holdings in Regeneron Pharmaceuticals were worth $6,031,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in REGN. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $28,000. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $36,000. Finally, Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Finally, Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $966.88.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $10.97 on Tuesday, reaching $561.81. The company's stock had a trading volume of 307,223 shares, compared to its average volume of 690,081. The stock's 50 day simple moving average is $674.46 and its two-hundred day simple moving average is $772.53. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $61.42 billion, a P/E ratio of 14.71, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 12-month low of $557.83 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 EPS. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.